CCND3 and cancer: Rapamycin has been tested alone and in combination with Janus Kinase (JAK), ABL protein inhibitors [84], focal adhesion kinase (FAK) or also with cyclin D3 (CCND3) and CDK4/6 inhibitors [89,90] in xenografts model and in in vitro cancer cell lines, showing relevant synergistic effects and induction of cellular mechanisms as autophagy.